Skip to content

Cellebrite

US · CLBT #2562 by market cap Listed 1970
10.77 -0.55 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 11.78 +4.06%
After-hours 11.23 +4.27%
16.6110.4410.772026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CLBT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -21.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 2.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 43.1x Better than 12%
Forward P/E 35.1x Better than 13%
Price / Sales 5.4x Better than 21%
P/E vs own 5-yr range 82nd pctl Better than 24%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 20.7% Better than 83%
Net income CAGR (3Y) -13.4% Better than 24%
Free cash flow CAGR (3Y) 140.7% Better than 96%
Profitability A-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 84.2% Better than 93%
Operating margin 14.0% Better than 62%
Net margin 16.4% Better than 74%
Return on equity 19.0% Better than 76%
Return on invested capital 13.5% Better than 79%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -2.5% Better than 68%
6-month return -18.3% Better than 29%
12-month return (ex latest month) -30.2% Better than 9%
Distance below 52-week high 44.5% Better than 24%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.6x Better than 43%
Debt to assets 2.4% Better than 87%
Interest coverage 174.4x Better than 95%
Free cash flow / net income 204.7% Better than 78%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 39.3% Better than 59%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.59%
1M -5.28%
3M -4.77%
6M -19.63%
YTD -40.27%
1Y -38.25%
3Y +34.96%
5Y +16.31%

Key statistics

Price & volume

Prev close
11.32
Open
11.18
Day range
10.72 - 11.41
Avg price
10.91
Volume
2.71M
Turnover
29.57M
Amplitude
6.10%
52-week range
9.58 - 19.39

Valuation

P/E
34.74
P/E (TTM)
43.08
P/B
4.67
EPS
0.31
Net profit
77.92M
Net assets
579.34M

Share structure

Market cap
2.71B
Float cap
1.21B
Shares out
251.34M
Float shares
112.43M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 12% of range
9.58 19.39

44.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-14.73M net over the window

Short interest

Shares short
5.64M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Cellebrite (CLBT)?

Cellebrite last traded at 10.77. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Cellebrite's market cap?

About 2.71B.

What is the P/E ratio of Cellebrite?

The trailing twelve-month P/E is 43.08, above its own 5-year average of 3.23 — toward the top of its historical range (82.14% percentile). See the Valuation tab for the full history.

Does Cellebrite pay a dividend?

Cellebrite does not currently pay a regular dividend.

Is Cellebrite a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 15.00, which implies 39.3% upside from the current price. This is not investment advice.

What is Cellebrite's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Cellebrite a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Cellebrite discussion 0 comments

Add a comment